甘草医生赴港IPO “开药返提成”涉嫌触碰监管红线

Core Viewpoint - The company Gan Cao Doctor, an online TCM diagnosis platform, has submitted its listing application to the Hong Kong Stock Exchange, with a valuation of 1.6 billion yuan in its latest financing round, benefiting from AI-assisted TCM diagnosis and the "Internet + TCM" trend [1] Group 1: Company Overview - Gan Cao Doctor is positioned as the largest online TCM comprehensive service provider in China, holding a 4.9% market share [1] - The company reported revenues of 600 million yuan, 690 million yuan, and 550 million yuan for the first three quarters of 2023, 2024, and 2025 respectively [1] - The net profit is expected to reach 10 million yuan in 2024, but the company anticipates a loss in the first three quarters of 2025 [1] Group 2: Operational Challenges - The company acknowledges that its operating performance is directly affected by sales costs, with fluctuations in procurement prices, supply chain disruptions, and seasonal variations in TCM materials potentially impacting unit costs [1] - There are concerns regarding the quality of registered physicians on the platform, as many do not have detailed qualifications, and some claim to specialize in a wide range of conditions without sufficient verification [2] - The platform's regulatory measures and compliance are questioned, with reports of potential kickbacks for physicians, which contradicts national regulations on medical practices [3]